All In Biotech

Drug Trial Radar · NCT02045901

A Multicenter Trial of the Efficacy and Safety of Diclegis® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents

Last checked: Nov 19, 2026Latest source record: Nov 23, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingRandomized with 131 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

131

Actual

Start

Feb 2014

Primary completion

Mar 31, 2017

Study completion Oct 2017

Sponsor

Lead sponsor
Duchesnay Inc.Industry
Sponsor type
Industry
Collaborators
Premier Research
First posted
Jan 27, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Female only, from 12 years, up to 17 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of this study is to compare the efficacy of Diclegis for the treatment of nausea and vomiting of pregnancy (NVP) in pregnant adolescents aged 12 to 17 years with placebo. The secondary objective of this study is to compare the safety of Diclegis in pregnant adolescents aged 12 to 17 years with placebo by assessing differences in the severity and occurrence of maternal adverse events (AEs).

Conditions

  • Morning Sickness

Interventions

  • DiclegisDrug

    On Day 1, all participants will take 2 tablets of Diclegis at bedtime. On Days 2 to 14, participants will take 2 tablets of Diclegis at bedtime. The minimum dosage will be 2 tablets daily at bedtime, increasing, when indicated, to the maximal dosage of 4 tablets per day on Days 3 to 14.

  • Placebo (Sugar Pill)Drug

    On Day 1, all participants will take 2 tablets of Placebo at bedtime. On Days 2 to 14, participants will take 2 tablets of Placebo at bedtime. The minimum dosage will be 2 tablets daily at bedtime, increasing, when indicated, to the maximal dosage of 4 tablets per day on Days 3 to 14.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Nausea and Vomiting of Pregnancy Severity from Baseline to Day 15Time frame: Day 1-Day 15

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Watching Over Mothers and Babies

    Tucson, Arizona

  • Clinica Del Socorro Medical Group, Inc.

    Los Angeles, California

  • Futura Research

    Norwalk, California

  • Medical Professional CR Center

    Miami, Florida

  • Empire Clinical Research, LLC

    Miami Lakes, Florida

  • Western Michigan University Homer Stryker M.D. School of Medicine

    Kalamazoo, Michigan

  • Jersey Shore University Medical Center

    Neptune City, New Jersey

  • Complete Healthcare for Women

    Columbus, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.